

LITERATURA

1. Ninlaro. Ceny a úhrady. Dostupné na: www.prehledysukl.cz (navštíveno 31. 5. 2023).
2. Revlimid. Ceny a úhrady. www.prehledysukl.cz.
3. Jackson GH, Davies FE, Pawlyn C, et al. UK NCRI Haemato-oncology Clinical Studies Group. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2019;20(1):57-73.
4. Jackson GH, Pawlyn C, Cairns DA, et al. UK NCRI Haemato-oncology Clinical Studies Group. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. *Br J Haematol*. 2021;192(5):853-868.
5. Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. *Blood Res*. 2020;55(S1):S43-S53.
6. Rajkumar SV, Harousseau JL, Durie B, et al. International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood*. 2011;117(18):4691-4695.
7. Nijhof IS, van de Donk NWCJ, Zweegman S, et al. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. *Drugs*. 2018;78(1):19-37.
8. Orłowski RZ, Lonial S. Integration of Novel Agents into the Care of Patients with Multiple Myeloma. *Clin Cancer Res*. 2016;22(22):5443-5452.
9. Baz R, Lin HM, Hui AM, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. *Support Care Cancer*. 2015;23(9):2789-2797.
10. Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. *Cancer Nurs*. 2013;36(4):301-308.
11. Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. *Blood*. 2012;120(5):927-928.
12. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun*. 2014;5:2997.
13. Brioli A, Melchor L, Cavo M, et al. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. *Br J Haematol*. 2014;165(4):441-454.
14. Dimopoulos MA, Richardson P, Lonial S. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2022;22(7):460-473.
15. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Hemasphere*. 2021;5(2):e528.
16. Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. *Hematology Am Soc Hematol Educ Program*. 2017;2017(1):508-517.
17. Dimopoulos MA, Moreau P, Terpos E, et al. EHA Guidelines Committee. ESMO Guidelines Committee. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(3):309-322.
18. Kunacheewa C, Feng L, Manasanch EE, et al. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. *Br J Haematol*. 2021;193(3):e23-e26.
19. Moreau P, Masszi T, Grzasko N, et al. TOURMALINE-MM1 Study Group. Oral ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016;374(17):1621-1634.
20. Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. *Haematologica*. 2017;102(10):1767-1775.
21. Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. *Blood Cancer J*. 2017;7(4):e554.
22. Dimopoulos MA, Oriol A, Nahi H, et al. POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016;375(14):1319-1331.
23. Richardson PG, Jagannath S, Moreau P, et al. 1703 study investigators. ELOTUZUMAB in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. *Lancet Haematol*. 2015;2(12):e516-527.
24. Lee HC, Ramasamy K, Marco M, et al. Impact of prior treatment exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients treated in routine clinical practice (the INSURE study). *HemaSphere*. 2022;6:815-816.

Chcete číst aktuální články časopisu **ONKOLOGIE ON-LINE?**

Řešením je ELEKTRONICKÉ PŘEDPLATNÉ



- **www.onkologiests.cz**
ČTĚTE IHNED v podobě listovačky či ve formátu PDF
- **bez přihlášení/předplatného** jsou články přístupné až **po 1 roce**
- **5 čísel/rok – 660 Kč** (vč. tematických příloh)

Objednávejte
v našem e-shopu →



www.solen.cz